There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments.
Repare Therapeutics (RPTX)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company’s shares closed last Friday at $15.23, close to its 52-week low of $13.97.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Repare Therapeutics is a Strong Buy with an average price target of $48.20.
See the top stocks recommended by analysts >>
Oramed Pharmaceuticals (ORMP)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Friday at $11.05.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Oramed Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $34.25.
Citius Pharmaceuticals (CTXR)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Citius Pharmaceuticals today and set a price target of $6.00. The company’s shares closed last Friday at $1.53, close to its 52-week low of $1.07.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RPTX:
- Tuesday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
- Needham Thinks DocGo’s Stock is Going to Recover
- H.C. Wainwright Thinks BridgeBio Pharma’s Stock is Going to Recover
- Accolade (ACCD) Received its Third Buy in a Row
- H.C. Wainwright Maintains Their Buy Rating on Taro Pharmaceutical (TARO)
